Home/Alumis/Claire Langrish
CL

Claire Langrish

SVP, Head of Immunology and Translational Science

Alumis

Alumis Pipeline

DrugIndicationPhase
Envudeucitinib (ESK-001)Moderate-to-Severe Plaque PsoriasisPhase 3
EnvudeucitinibModerate-to-Severe Systemic Lupus ErythematosusPhase 2
A-005Undisclosed Immune-Mediated DiseaseDiscovery/Preclinical